About structure therapeutics inc. - GPCR
Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in February 2019 and is headquartered in South San Francisco, CA.
GPCR At a Glance
Structure Therapeutics, Inc.
601 Gateway Boulevard
South San Francisco, California 94080
| Phone | 1-650-457-1978 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -122,587,456.38 | |
| Sector | Health Technology | Employees | 163 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
GPCR Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.796 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -3.519 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.007 |
GPCR Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -752,070.285 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
GPCR Liquidity
| Current Ratio | 24.741 |
| Quick Ratio | 24.741 |
| Cash Ratio | 24.528 |
GPCR Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -17.698 |
| Return on Equity | -18.605 |
| Return on Total Capital | -14.112 |
| Return on Invested Capital | -18.518 |
GPCR Capital Structure
| Total Debt to Total Equity | 0.447 |
| Total Debt to Total Capital | 0.445 |
| Total Debt to Total Assets | 0.428 |
| Long-Term Debt to Equity | 0.25 |
| Long-Term Debt to Total Capital | 0.249 |